Phase 3 Clinical Trials With Primary Completion Dates in July 2016

This is a list of Phase 3 trials with primary completion dates in July 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ANTHAnthera Pharmaceuticals, Inc.2016-07-01Phase 3NCT01395745CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus
ARDMAradigm Corporation2016-07-01Phase 3NCT02104245Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis
ARDMAradigm Corporation2016-07-01Phase 3NCT01515007Phase 3 Study With Dual Release Ciprofloxacin for Inhalation in Non-CF Bronchiectasis
EVOKEvoke Pharma, Inc.2016-07-01Phase 3NCT02025751Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis
EVOKEvoke Pharma, Inc.2016-07-01Phase 3NCT02025725Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis
FGENFibroGen, Inc2016-07-01Phase 3NCT02652819FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis
JAZZJazz Pharmaceuticals plc2016-07-01Phase 3NCT00628498Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
NVCRNovoCure Limited2016-07-01Phase 3NCT00916409Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
ONTXOnconova Therapeutics, Inc.2016-07-01Phase 3NCT01241500Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
OPHTOphthotech Corporation2016-07-01Phase 3NCT01944839A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
OPHTOphthotech Corporation2016-07-01Phase 3NCT01940900A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
OPHTOphthotech Corporation2016-07-01Phase 3NCT01940887A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
OTICOtonomy, Inc.2016-07-01Phase 3NCT02600559Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes
PRAHPRA Health Sciences, Inc.2016-07-01Phase 3NCT02338960A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
PTNPalatin Technologies, Inc.2016-07-01Phase 3NCT02338960A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
RDHLRedhill Biopharma Ltd.2016-07-01Phase 3NCT01951326Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease
RDYDr. Reddy's Laboratories Ltd2016-07-01Phase 3NCT02572986A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies
SGYPSynergy Pharmaceuticals, Inc.2016-07-01Phase 3NCT02493452Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
SGYPUSynergy Pharmaceuticals, Inc.2016-07-01Phase 3NCT02493452Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
TENXTenax Therapeutics, Inc.2016-07-01Phase 3NCT02025621Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass
VRXValeant Pharmaceuticals International, Inc.2016-07-01Phase 3NCT02535871A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
VRXValeant Pharmaceuticals International, Inc.2016-07-01Phase 3NCT02491060A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
VRXValeant Pharmaceuticals International, Inc.2016-07-01Phase 3NCT02462083Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
VRXValeant Pharmaceuticals International, Inc.2016-07-01Phase 3NCT02515097Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis
VRXValeant Pharmaceuticals International, Inc.2016-07-01Phase 3NCT02514577Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis